nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—HTR3A—myenteric nerve plexus—stomach cancer	0.069	0.327	CbGeAlD
Metoclopramide—HTR3A—vagus nerve—stomach cancer	0.046	0.218	CbGeAlD
Metoclopramide—CYP11B2—hematopoietic system—stomach cancer	0.0157	0.0742	CbGeAlD
Metoclopramide—CYP11B1—hematopoietic system—stomach cancer	0.0157	0.0742	CbGeAlD
Metoclopramide—CYP11B2—endocrine gland—stomach cancer	0.009	0.0426	CbGeAlD
Metoclopramide—CYP11B1—endocrine gland—stomach cancer	0.009	0.0426	CbGeAlD
Metoclopramide—HTR3A—hematopoietic system—stomach cancer	0.00751	0.0356	CbGeAlD
Metoclopramide—Sunitinib—PRKAA1—stomach cancer	0.00636	0.234	CrCbGaD
Metoclopramide—Sunitinib—FYN—stomach cancer	0.00636	0.234	CrCbGaD
Metoclopramide—CYP11B2—lymph node—stomach cancer	0.00622	0.0295	CbGeAlD
Metoclopramide—CYP17A1—endocrine gland—stomach cancer	0.0055	0.026	CbGeAlD
Metoclopramide—HTR3A—digestive system—stomach cancer	0.00522	0.0247	CbGeAlD
Metoclopramide—CYP17A1—liver—stomach cancer	0.00496	0.0235	CbGeAlD
Metoclopramide—Sunitinib—CHEK2—stomach cancer	0.00432	0.159	CrCbGaD
Metoclopramide—Sunitinib—FGFR2—stomach cancer	0.00403	0.148	CrCbGaD
Metoclopramide—CYP17A1—lymph node—stomach cancer	0.0038	0.018	CbGeAlD
Metoclopramide—Procainamide—DNMT1—stomach cancer	0.00376	0.138	CrCbGaD
Metoclopramide—CHRM1—endocrine gland—stomach cancer	0.00328	0.0155	CbGeAlD
Metoclopramide—CYP2D6—hematopoietic system—stomach cancer	0.00276	0.0131	CbGeAlD
Metoclopramide—DRD2—endocrine gland—stomach cancer	0.00264	0.0125	CbGeAlD
Metoclopramide—Cisapride—CYP2A6—stomach cancer	0.00237	0.0872	CrCbGaD
Metoclopramide—Headache—Floxuridine—stomach cancer	0.00212	0.00545	CcSEcCtD
Metoclopramide—Body temperature increased—Mitomycin—stomach cancer	0.0021	0.00539	CcSEcCtD
Metoclopramide—Urinary incontinence—Capecitabine—stomach cancer	0.00209	0.00537	CcSEcCtD
Metoclopramide—Hepatotoxicity—Methotrexate—stomach cancer	0.00209	0.00536	CcSEcCtD
Metoclopramide—Fluid retention—Capecitabine—stomach cancer	0.00205	0.00528	CcSEcCtD
Metoclopramide—Nausea—Floxuridine—stomach cancer	0.00201	0.00516	CcSEcCtD
Metoclopramide—CYP2D6—digestive system—stomach cancer	0.00192	0.00909	CbGeAlD
Metoclopramide—Asthenia—Mitomycin—stomach cancer	0.00191	0.00489	CcSEcCtD
Metoclopramide—Neutropenia—Irinotecan—stomach cancer	0.0019	0.00487	CcSEcCtD
Metoclopramide—Diarrhoea—Mitomycin—stomach cancer	0.00182	0.00467	CcSEcCtD
Metoclopramide—Blood disorder—Epirubicin—stomach cancer	0.00181	0.00464	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Docetaxel—stomach cancer	0.00179	0.00459	CcSEcCtD
Metoclopramide—Jaundice—Irinotecan—stomach cancer	0.00176	0.00453	CcSEcCtD
Metoclopramide—Dizziness—Mitomycin—stomach cancer	0.00176	0.00451	CcSEcCtD
Metoclopramide—Delirium—Epirubicin—stomach cancer	0.00175	0.0045	CcSEcCtD
Metoclopramide—Amenorrhoea—Epirubicin—stomach cancer	0.00172	0.00441	CcSEcCtD
Metoclopramide—Visual disturbance—Docetaxel—stomach cancer	0.00171	0.0044	CcSEcCtD
Metoclopramide—Atrial fibrillation—Docetaxel—stomach cancer	0.00171	0.0044	CcSEcCtD
Metoclopramide—Renal impairment—Docetaxel—stomach cancer	0.00171	0.00438	CcSEcCtD
Metoclopramide—Rash—Mitomycin—stomach cancer	0.00168	0.0043	CcSEcCtD
Metoclopramide—Dermatitis—Mitomycin—stomach cancer	0.00167	0.0043	CcSEcCtD
Metoclopramide—Blood disorder—Doxorubicin—stomach cancer	0.00167	0.00429	CcSEcCtD
Metoclopramide—Headache—Mitomycin—stomach cancer	0.00166	0.00427	CcSEcCtD
Metoclopramide—Atrial fibrillation—Capecitabine—stomach cancer	0.00166	0.00426	CcSEcCtD
Metoclopramide—Bradycardia—Irinotecan—stomach cancer	0.00165	0.00424	CcSEcCtD
Metoclopramide—Renal impairment—Capecitabine—stomach cancer	0.00165	0.00424	CcSEcCtD
Metoclopramide—Respiratory failure—Methotrexate—stomach cancer	0.00164	0.00421	CcSEcCtD
Metoclopramide—Delirium—Doxorubicin—stomach cancer	0.00162	0.00416	CcSEcCtD
Metoclopramide—Agranulocytosis—Fluorouracil—stomach cancer	0.00162	0.00415	CcSEcCtD
Metoclopramide—Dyskinesia—Epirubicin—stomach cancer	0.0016	0.00412	CcSEcCtD
Metoclopramide—Amenorrhoea—Doxorubicin—stomach cancer	0.00159	0.00408	CcSEcCtD
Metoclopramide—CYP2D6—endocrine gland—stomach cancer	0.00159	0.00751	CbGeAlD
Metoclopramide—Nausea—Mitomycin—stomach cancer	0.00158	0.00405	CcSEcCtD
Metoclopramide—Visual impairment—Irinotecan—stomach cancer	0.00157	0.00402	CcSEcCtD
Metoclopramide—Atrioventricular block—Epirubicin—stomach cancer	0.00155	0.00399	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Epirubicin—stomach cancer	0.00151	0.00387	CcSEcCtD
Metoclopramide—Flushing—Irinotecan—stomach cancer	0.00151	0.00387	CcSEcCtD
Metoclopramide—Cardiac arrest—Capecitabine—stomach cancer	0.00149	0.00384	CcSEcCtD
Metoclopramide—Dyskinesia—Doxorubicin—stomach cancer	0.00148	0.00381	CcSEcCtD
Metoclopramide—Gynaecomastia—Methotrexate—stomach cancer	0.00144	0.0037	CcSEcCtD
Metoclopramide—Atrioventricular block—Doxorubicin—stomach cancer	0.00144	0.00369	CcSEcCtD
Metoclopramide—Fluid retention—Epirubicin—stomach cancer	0.00143	0.00368	CcSEcCtD
Metoclopramide—CYP2D6—liver—stomach cancer	0.00143	0.00677	CbGeAlD
Metoclopramide—Ventricular tachycardia—Doxorubicin—stomach cancer	0.0014	0.00358	CcSEcCtD
Metoclopramide—Bronchospasm—Docetaxel—stomach cancer	0.00138	0.00354	CcSEcCtD
Metoclopramide—Rash maculo-papular—Epirubicin—stomach cancer	0.00137	0.00352	CcSEcCtD
Metoclopramide—Muscle spasms—Irinotecan—stomach cancer	0.00136	0.00349	CcSEcCtD
Metoclopramide—Asthma—Capecitabine—stomach cancer	0.00136	0.00349	CcSEcCtD
Metoclopramide—Bronchospasm—Capecitabine—stomach cancer	0.00134	0.00343	CcSEcCtD
Metoclopramide—Fluid retention—Doxorubicin—stomach cancer	0.00132	0.0034	CcSEcCtD
Metoclopramide—Neutropenia—Docetaxel—stomach cancer	0.00131	0.00337	CcSEcCtD
Metoclopramide—Neutropenia—Capecitabine—stomach cancer	0.00127	0.00326	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—stomach cancer	0.00127	0.00326	CcSEcCtD
Metoclopramide—Leukopenia—Irinotecan—stomach cancer	0.00127	0.00325	CcSEcCtD
Metoclopramide—Visual disturbance—Methotrexate—stomach cancer	0.00123	0.00317	CcSEcCtD
Metoclopramide—Hypertension—Irinotecan—stomach cancer	0.00122	0.00313	CcSEcCtD
Metoclopramide—Jaundice—Docetaxel—stomach cancer	0.00122	0.00313	CcSEcCtD
Metoclopramide—Leukopenia—Fluorouracil—stomach cancer	0.00121	0.00311	CcSEcCtD
Metoclopramide—Depression—Capecitabine—stomach cancer	0.00121	0.0031	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Epirubicin—stomach cancer	0.00121	0.0031	CcSEcCtD
Metoclopramide—Jaundice—Capecitabine—stomach cancer	0.00118	0.00303	CcSEcCtD
Metoclopramide—Convulsion—Fluorouracil—stomach cancer	0.00117	0.00301	CcSEcCtD
Metoclopramide—Agranulocytosis—Docetaxel—stomach cancer	0.00117	0.003	CcSEcCtD
Metoclopramide—Confusional state—Irinotecan—stomach cancer	0.00116	0.00299	CcSEcCtD
Metoclopramide—Oedema—Irinotecan—stomach cancer	0.00115	0.00296	CcSEcCtD
Metoclopramide—Renal impairment—Epirubicin—stomach cancer	0.00115	0.00295	CcSEcCtD
Metoclopramide—Agranulocytosis—Capecitabine—stomach cancer	0.00113	0.0029	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—stomach cancer	0.00112	0.00287	CcSEcCtD
Metoclopramide—Confusional state—Fluorouracil—stomach cancer	0.00111	0.00286	CcSEcCtD
Metoclopramide—Bradycardia—Capecitabine—stomach cancer	0.00111	0.00284	CcSEcCtD
Metoclopramide—Oedema—Fluorouracil—stomach cancer	0.00111	0.00284	CcSEcCtD
Metoclopramide—Visual impairment—Docetaxel—stomach cancer	0.00108	0.00278	CcSEcCtD
Metoclopramide—Tachycardia—Fluorouracil—stomach cancer	0.00108	0.00277	CcSEcCtD
Metoclopramide—Hypotension—Irinotecan—stomach cancer	0.00108	0.00277	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—stomach cancer	0.00106	0.00273	CcSEcCtD
Metoclopramide—Visual impairment—Capecitabine—stomach cancer	0.00105	0.00269	CcSEcCtD
Metoclopramide—Insomnia—Irinotecan—stomach cancer	0.00104	0.00268	CcSEcCtD
Metoclopramide—Flushing—Docetaxel—stomach cancer	0.00104	0.00268	CcSEcCtD
Metoclopramide—Cardiac arrest—Epirubicin—stomach cancer	0.00104	0.00267	CcSEcCtD
Metoclopramide—Hypotension—Fluorouracil—stomach cancer	0.00103	0.00265	CcSEcCtD
Metoclopramide—Dyspnoea—Irinotecan—stomach cancer	0.00103	0.00264	CcSEcCtD
Metoclopramide—Somnolence—Irinotecan—stomach cancer	0.00103	0.00263	CcSEcCtD
Metoclopramide—Asthma—Methotrexate—stomach cancer	0.00101	0.0026	CcSEcCtD
Metoclopramide—Flushing—Capecitabine—stomach cancer	0.00101	0.00259	CcSEcCtD
Metoclopramide—Insomnia—Fluorouracil—stomach cancer	0.000999	0.00257	CcSEcCtD
Metoclopramide—Fatigue—Irinotecan—stomach cancer	0.000995	0.00255	CcSEcCtD
Metoclopramide—Dyspnoea—Fluorouracil—stomach cancer	0.000985	0.00253	CcSEcCtD
Metoclopramide—Somnolence—Fluorouracil—stomach cancer	0.000982	0.00252	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—stomach cancer	0.000963	0.00247	CcSEcCtD
Metoclopramide—Feeling abnormal—Irinotecan—stomach cancer	0.000951	0.00244	CcSEcCtD
Metoclopramide—Asthma—Epirubicin—stomach cancer	0.000946	0.00243	CcSEcCtD
Metoclopramide—Neutropenia—Methotrexate—stomach cancer	0.000945	0.00243	CcSEcCtD
Metoclopramide—Muscle spasms—Docetaxel—stomach cancer	0.00094	0.00241	CcSEcCtD
Metoclopramide—Erectile dysfunction—Methotrexate—stomach cancer	0.000931	0.00239	CcSEcCtD
Metoclopramide—Body temperature increased—Irinotecan—stomach cancer	0.000912	0.00234	CcSEcCtD
Metoclopramide—Feeling abnormal—Fluorouracil—stomach cancer	0.000911	0.00234	CcSEcCtD
Metoclopramide—Muscle spasms—Capecitabine—stomach cancer	0.00091	0.00234	CcSEcCtD
Metoclopramide—Drowsiness—Methotrexate—stomach cancer	0.000901	0.00231	CcSEcCtD
Metoclopramide—Depression—Methotrexate—stomach cancer	0.000899	0.00231	CcSEcCtD
Metoclopramide—Tremor—Capecitabine—stomach cancer	0.000886	0.00228	CcSEcCtD
Metoclopramide—Neutropenia—Epirubicin—stomach cancer	0.000885	0.00227	CcSEcCtD
Metoclopramide—Urticaria—Fluorouracil—stomach cancer	0.000878	0.00225	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—stomach cancer	0.000875	0.00225	CcSEcCtD
Metoclopramide—Leukopenia—Docetaxel—stomach cancer	0.000875	0.00225	CcSEcCtD
Metoclopramide—Pollakiuria—Epirubicin—stomach cancer	0.000874	0.00224	CcSEcCtD
Metoclopramide—Body temperature increased—Fluorouracil—stomach cancer	0.000874	0.00224	CcSEcCtD
Metoclopramide—Palpitations—Docetaxel—stomach cancer	0.000864	0.00222	CcSEcCtD
Metoclopramide—Hypersensitivity—Irinotecan—stomach cancer	0.00085	0.00218	CcSEcCtD
Metoclopramide—Leukopenia—Capecitabine—stomach cancer	0.000847	0.00217	CcSEcCtD
Metoclopramide—Convulsion—Docetaxel—stomach cancer	0.000847	0.00217	CcSEcCtD
Metoclopramide—Hypertension—Docetaxel—stomach cancer	0.000844	0.00217	CcSEcCtD
Metoclopramide—Drowsiness—Epirubicin—stomach cancer	0.000843	0.00217	CcSEcCtD
Metoclopramide—Agranulocytosis—Methotrexate—stomach cancer	0.000841	0.00216	CcSEcCtD
Metoclopramide—Palpitations—Capecitabine—stomach cancer	0.000836	0.00215	CcSEcCtD
Metoclopramide—Asthenia—Irinotecan—stomach cancer	0.000828	0.00213	CcSEcCtD
Metoclopramide—Jaundice—Epirubicin—stomach cancer	0.000822	0.00211	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—stomach cancer	0.000819	0.0021	CcSEcCtD
Metoclopramide—Hypertension—Capecitabine—stomach cancer	0.000817	0.0021	CcSEcCtD
Metoclopramide—Hypersensitivity—Fluorouracil—stomach cancer	0.000814	0.00209	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—stomach cancer	0.000809	0.00208	CcSEcCtD
Metoclopramide—Confusional state—Docetaxel—stomach cancer	0.000804	0.00206	CcSEcCtD
Metoclopramide—Anxiety—Capecitabine—stomach cancer	0.000803	0.00206	CcSEcCtD
Metoclopramide—Oedema—Docetaxel—stomach cancer	0.000798	0.00205	CcSEcCtD
Metoclopramide—Diarrhoea—Irinotecan—stomach cancer	0.000789	0.00203	CcSEcCtD
Metoclopramide—Agranulocytosis—Epirubicin—stomach cancer	0.000787	0.00202	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—stomach cancer	0.00078	0.002	CcSEcCtD
Metoclopramide—Visual impairment—Methotrexate—stomach cancer	0.00078	0.002	CcSEcCtD
Metoclopramide—Confusional state—Capecitabine—stomach cancer	0.000779	0.002	CcSEcCtD
Metoclopramide—Tachycardia—Docetaxel—stomach cancer	0.000778	0.002	CcSEcCtD
Metoclopramide—Oedema—Capecitabine—stomach cancer	0.000772	0.00198	CcSEcCtD
Metoclopramide—Bradycardia—Epirubicin—stomach cancer	0.000771	0.00198	CcSEcCtD
Metoclopramide—Dizziness—Irinotecan—stomach cancer	0.000763	0.00196	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—stomach cancer	0.000761	0.00195	CcSEcCtD
Metoclopramide—Diarrhoea—Fluorouracil—stomach cancer	0.000756	0.00194	CcSEcCtD
Metoclopramide—Tachycardia—Capecitabine—stomach cancer	0.000754	0.00194	CcSEcCtD
Metoclopramide—Hypotension—Docetaxel—stomach cancer	0.000745	0.00191	CcSEcCtD
Metoclopramide—Dizziness—Fluorouracil—stomach cancer	0.000731	0.00188	CcSEcCtD
Metoclopramide—Visual impairment—Epirubicin—stomach cancer	0.00073	0.00187	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—stomach cancer	0.000728	0.00187	CcSEcCtD
Metoclopramide—Rash—Irinotecan—stomach cancer	0.000727	0.00187	CcSEcCtD
Metoclopramide—Dermatitis—Irinotecan—stomach cancer	0.000727	0.00187	CcSEcCtD
Metoclopramide—Headache—Irinotecan—stomach cancer	0.000723	0.00186	CcSEcCtD
Metoclopramide—Hypotension—Capecitabine—stomach cancer	0.000722	0.00185	CcSEcCtD
Metoclopramide—Insomnia—Docetaxel—stomach cancer	0.000721	0.00185	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—stomach cancer	0.000713	0.00183	CcSEcCtD
Metoclopramide—Dyspnoea—Docetaxel—stomach cancer	0.000711	0.00183	CcSEcCtD
Metoclopramide—Somnolence—Docetaxel—stomach cancer	0.000709	0.00182	CcSEcCtD
Metoclopramide—Flushing—Epirubicin—stomach cancer	0.000703	0.0018	CcSEcCtD
Metoclopramide—Insomnia—Capecitabine—stomach cancer	0.000698	0.00179	CcSEcCtD
Metoclopramide—Rash—Fluorouracil—stomach cancer	0.000697	0.00179	CcSEcCtD
Metoclopramide—Dermatitis—Fluorouracil—stomach cancer	0.000696	0.00179	CcSEcCtD
Metoclopramide—Headache—Fluorouracil—stomach cancer	0.000692	0.00178	CcSEcCtD
Metoclopramide—Dyspnoea—Capecitabine—stomach cancer	0.000688	0.00177	CcSEcCtD
Metoclopramide—Fatigue—Docetaxel—stomach cancer	0.000688	0.00177	CcSEcCtD
Metoclopramide—Nausea—Irinotecan—stomach cancer	0.000685	0.00176	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—stomach cancer	0.000675	0.00173	CcSEcCtD
Metoclopramide—Fatigue—Capecitabine—stomach cancer	0.000666	0.00171	CcSEcCtD
Metoclopramide—Feeling abnormal—Docetaxel—stomach cancer	0.000657	0.00169	CcSEcCtD
Metoclopramide—Nausea—Fluorouracil—stomach cancer	0.000656	0.00169	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—stomach cancer	0.00065	0.00167	CcSEcCtD
Metoclopramide—Nervousness—Epirubicin—stomach cancer	0.00064	0.00164	CcSEcCtD
Metoclopramide—Feeling abnormal—Capecitabine—stomach cancer	0.000636	0.00163	CcSEcCtD
Metoclopramide—Muscle spasms—Epirubicin—stomach cancer	0.000634	0.00163	CcSEcCtD
Metoclopramide—Body temperature increased—Docetaxel—stomach cancer	0.000631	0.00162	CcSEcCtD
Metoclopramide—Leukopenia—Methotrexate—stomach cancer	0.00063	0.00162	CcSEcCtD
Metoclopramide—Urticaria—Capecitabine—stomach cancer	0.000613	0.00158	CcSEcCtD
Metoclopramide—Body temperature increased—Capecitabine—stomach cancer	0.00061	0.00157	CcSEcCtD
Metoclopramide—Convulsion—Methotrexate—stomach cancer	0.00061	0.00157	CcSEcCtD
Metoclopramide—Agitation—Epirubicin—stomach cancer	0.000606	0.00156	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—stomach cancer	0.000592	0.00152	CcSEcCtD
Metoclopramide—Leukopenia—Epirubicin—stomach cancer	0.00059	0.00151	CcSEcCtD
Metoclopramide—Hypersensitivity—Docetaxel—stomach cancer	0.000588	0.00151	CcSEcCtD
Metoclopramide—Muscle spasms—Doxorubicin—stomach cancer	0.000586	0.00151	CcSEcCtD
Metoclopramide—Palpitations—Epirubicin—stomach cancer	0.000583	0.0015	CcSEcCtD
Metoclopramide—Confusional state—Methotrexate—stomach cancer	0.00058	0.00149	CcSEcCtD
Metoclopramide—Asthenia—Docetaxel—stomach cancer	0.000572	0.00147	CcSEcCtD
Metoclopramide—Convulsion—Epirubicin—stomach cancer	0.000571	0.00147	CcSEcCtD
Metoclopramide—Hypertension—Epirubicin—stomach cancer	0.000569	0.00146	CcSEcCtD
Metoclopramide—Hypersensitivity—Capecitabine—stomach cancer	0.000569	0.00146	CcSEcCtD
Metoclopramide—Agitation—Doxorubicin—stomach cancer	0.00056	0.00144	CcSEcCtD
Metoclopramide—Anxiety—Epirubicin—stomach cancer	0.000559	0.00144	CcSEcCtD
Metoclopramide—Asthenia—Capecitabine—stomach cancer	0.000554	0.00142	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—stomach cancer	0.000546	0.0014	CcSEcCtD
Metoclopramide—Diarrhoea—Docetaxel—stomach cancer	0.000546	0.0014	CcSEcCtD
Metoclopramide—Confusional state—Epirubicin—stomach cancer	0.000542	0.00139	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—stomach cancer	0.000539	0.00138	CcSEcCtD
Metoclopramide—Oedema—Epirubicin—stomach cancer	0.000538	0.00138	CcSEcCtD
Metoclopramide—Hypotension—Methotrexate—stomach cancer	0.000537	0.00138	CcSEcCtD
Metoclopramide—Convulsion—Doxorubicin—stomach cancer	0.000528	0.00136	CcSEcCtD
Metoclopramide—Diarrhoea—Capecitabine—stomach cancer	0.000528	0.00136	CcSEcCtD
Metoclopramide—Dizziness—Docetaxel—stomach cancer	0.000527	0.00135	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—stomach cancer	0.000527	0.00135	CcSEcCtD
Metoclopramide—Tachycardia—Epirubicin—stomach cancer	0.000525	0.00135	CcSEcCtD
Metoclopramide—Insomnia—Methotrexate—stomach cancer	0.00052	0.00133	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—stomach cancer	0.000517	0.00133	CcSEcCtD
Metoclopramide—Dyspnoea—Methotrexate—stomach cancer	0.000513	0.00132	CcSEcCtD
Metoclopramide—Somnolence—Methotrexate—stomach cancer	0.000511	0.00131	CcSEcCtD
Metoclopramide—Dizziness—Capecitabine—stomach cancer	0.000511	0.00131	CcSEcCtD
Metoclopramide—Rash—Docetaxel—stomach cancer	0.000503	0.00129	CcSEcCtD
Metoclopramide—Hypotension—Epirubicin—stomach cancer	0.000503	0.00129	CcSEcCtD
Metoclopramide—Dermatitis—Docetaxel—stomach cancer	0.000502	0.00129	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—stomach cancer	0.000502	0.00129	CcSEcCtD
Metoclopramide—Headache—Docetaxel—stomach cancer	0.0005	0.00128	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—stomach cancer	0.000498	0.00128	CcSEcCtD
Metoclopramide—Fatigue—Methotrexate—stomach cancer	0.000496	0.00127	CcSEcCtD
Metoclopramide—Rash—Capecitabine—stomach cancer	0.000487	0.00125	CcSEcCtD
Metoclopramide—Insomnia—Epirubicin—stomach cancer	0.000487	0.00125	CcSEcCtD
Metoclopramide—Dermatitis—Capecitabine—stomach cancer	0.000486	0.00125	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—stomach cancer	0.000486	0.00125	CcSEcCtD
Metoclopramide—Headache—Capecitabine—stomach cancer	0.000484	0.00124	CcSEcCtD
Metoclopramide—Dyspnoea—Epirubicin—stomach cancer	0.00048	0.00123	CcSEcCtD
Metoclopramide—Somnolence—Epirubicin—stomach cancer	0.000478	0.00123	CcSEcCtD
Metoclopramide—Nausea—Docetaxel—stomach cancer	0.000474	0.00122	CcSEcCtD
Metoclopramide—Feeling abnormal—Methotrexate—stomach cancer	0.000474	0.00122	CcSEcCtD
Metoclopramide—Hypotension—Doxorubicin—stomach cancer	0.000465	0.00119	CcSEcCtD
Metoclopramide—Fatigue—Epirubicin—stomach cancer	0.000464	0.00119	CcSEcCtD
Metoclopramide—Nausea—Capecitabine—stomach cancer	0.000459	0.00118	CcSEcCtD
Metoclopramide—Urticaria—Methotrexate—stomach cancer	0.000457	0.00117	CcSEcCtD
Metoclopramide—Body temperature increased—Methotrexate—stomach cancer	0.000454	0.00117	CcSEcCtD
Metoclopramide—Insomnia—Doxorubicin—stomach cancer	0.00045	0.00116	CcSEcCtD
Metoclopramide—Dyspnoea—Doxorubicin—stomach cancer	0.000444	0.00114	CcSEcCtD
Metoclopramide—Feeling abnormal—Epirubicin—stomach cancer	0.000443	0.00114	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—stomach cancer	0.000443	0.00114	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—stomach cancer	0.000429	0.0011	CcSEcCtD
Metoclopramide—Urticaria—Epirubicin—stomach cancer	0.000427	0.0011	CcSEcCtD
Metoclopramide—Body temperature increased—Epirubicin—stomach cancer	0.000425	0.00109	CcSEcCtD
Metoclopramide—Hypersensitivity—Methotrexate—stomach cancer	0.000424	0.00109	CcSEcCtD
Metoclopramide—Asthenia—Methotrexate—stomach cancer	0.000412	0.00106	CcSEcCtD
Metoclopramide—Feeling abnormal—Doxorubicin—stomach cancer	0.00041	0.00105	CcSEcCtD
Metoclopramide—Hypersensitivity—Epirubicin—stomach cancer	0.000396	0.00102	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—stomach cancer	0.000395	0.00102	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—stomach cancer	0.000393	0.00101	CcSEcCtD
Metoclopramide—Diarrhoea—Methotrexate—stomach cancer	0.000393	0.00101	CcSEcCtD
Metoclopramide—Asthenia—Epirubicin—stomach cancer	0.000386	0.000991	CcSEcCtD
Metoclopramide—Dizziness—Methotrexate—stomach cancer	0.00038	0.000976	CcSEcCtD
Metoclopramide—Diarrhoea—Epirubicin—stomach cancer	0.000368	0.000945	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—stomach cancer	0.000367	0.000942	CcSEcCtD
Metoclopramide—Rash—Methotrexate—stomach cancer	0.000362	0.000931	CcSEcCtD
Metoclopramide—Dermatitis—Methotrexate—stomach cancer	0.000362	0.00093	CcSEcCtD
Metoclopramide—Headache—Methotrexate—stomach cancer	0.00036	0.000925	CcSEcCtD
Metoclopramide—Asthenia—Doxorubicin—stomach cancer	0.000357	0.000917	CcSEcCtD
Metoclopramide—Dizziness—Epirubicin—stomach cancer	0.000356	0.000913	CcSEcCtD
Metoclopramide—Nausea—Methotrexate—stomach cancer	0.000341	0.000877	CcSEcCtD
Metoclopramide—Diarrhoea—Doxorubicin—stomach cancer	0.000341	0.000874	CcSEcCtD
Metoclopramide—Rash—Epirubicin—stomach cancer	0.000339	0.000871	CcSEcCtD
Metoclopramide—Dermatitis—Epirubicin—stomach cancer	0.000339	0.00087	CcSEcCtD
Metoclopramide—Headache—Epirubicin—stomach cancer	0.000337	0.000865	CcSEcCtD
Metoclopramide—Dizziness—Doxorubicin—stomach cancer	0.000329	0.000845	CcSEcCtD
Metoclopramide—Nausea—Epirubicin—stomach cancer	0.00032	0.00082	CcSEcCtD
Metoclopramide—Rash—Doxorubicin—stomach cancer	0.000314	0.000806	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—stomach cancer	0.000314	0.000805	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—stomach cancer	0.000312	0.000801	CcSEcCtD
Metoclopramide—Nausea—Doxorubicin—stomach cancer	0.000296	0.000759	CcSEcCtD
Metoclopramide—DRD2—Signaling Pathways—FGG—stomach cancer	7.74e-05	0.000208	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—ADRB2—stomach cancer	7.64e-05	0.000205	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CDKN1B—stomach cancer	7.62e-05	0.000205	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGG—stomach cancer	7.58e-05	0.000204	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—IL6—stomach cancer	7.56e-05	0.000203	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PRKCB—stomach cancer	7.54e-05	0.000203	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ANXA1—stomach cancer	7.52e-05	0.000202	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PPP2R1A—stomach cancer	7.49e-05	0.000201	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—ADRB2—stomach cancer	7.48e-05	0.000201	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PRKAA1—stomach cancer	7.45e-05	0.0002	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALDH7A1—stomach cancer	7.43e-05	0.0002	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PLCE1—stomach cancer	7.43e-05	0.0002	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL6—stomach cancer	7.42e-05	0.000199	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—IL6—stomach cancer	7.4e-05	0.000199	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PPARG—stomach cancer	7.37e-05	0.000198	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PPP2R1A—stomach cancer	7.33e-05	0.000197	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—stomach cancer	7.33e-05	0.000197	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PRKAA1—stomach cancer	7.29e-05	0.000196	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ADRB1—stomach cancer	7.28e-05	0.000196	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCND1—stomach cancer	7.27e-05	0.000195	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—JUN—stomach cancer	7.26e-05	0.000195	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RBP4—stomach cancer	7.2e-05	0.000193	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTGS2—stomach cancer	7.2e-05	0.000193	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CXCL8—stomach cancer	7.19e-05	0.000193	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—UMPS—stomach cancer	7.13e-05	0.000192	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ALB—stomach cancer	7.09e-05	0.00019	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MMP9—stomach cancer	7.06e-05	0.00019	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RBP4—stomach cancer	7.04e-05	0.000189	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CXCL8—stomach cancer	7.04e-05	0.000189	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CDKN1A—stomach cancer	7.03e-05	0.000189	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—stomach cancer	7.01e-05	0.000188	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RPS6—stomach cancer	6.96e-05	0.000187	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK8—stomach cancer	6.87e-05	0.000184	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PRKCB—stomach cancer	6.85e-05	0.000184	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6ST—stomach cancer	6.82e-05	0.000183	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—NOS3—stomach cancer	6.78e-05	0.000182	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ALB—stomach cancer	6.63e-05	0.000178	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PDHA1—stomach cancer	6.63e-05	0.000178	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ECHS1—stomach cancer	6.63e-05	0.000178	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HBEGF—stomach cancer	6.39e-05	0.000172	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—NOS3—stomach cancer	6.34e-05	0.00017	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VEGFA—stomach cancer	6.34e-05	0.00017	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—STAT3—stomach cancer	6.28e-05	0.000169	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—FADS1—stomach cancer	6.23e-05	0.000167	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMP—stomach cancer	6.23e-05	0.000167	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTGS2—stomach cancer	6.2e-05	0.000167	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HSPB1—stomach cancer	6.19e-05	0.000166	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AGTR2—stomach cancer	6.19e-05	0.000166	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—F2R—stomach cancer	6.12e-05	0.000164	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—BMP2—stomach cancer	6.12e-05	0.000164	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6R—stomach cancer	6.08e-05	0.000163	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HSPB1—stomach cancer	6.06e-05	0.000163	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AGTR2—stomach cancer	6.06e-05	0.000163	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—RHOA—stomach cancer	6.05e-05	0.000163	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKR1C3—stomach cancer	6.02e-05	0.000162	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK3—stomach cancer	6e-05	0.000161	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—BMP2—stomach cancer	5.99e-05	0.000161	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—F2R—stomach cancer	5.99e-05	0.000161	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HTR1A—stomach cancer	5.96e-05	0.00016	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ADRB2—stomach cancer	5.9e-05	0.000159	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKR1C3—stomach cancer	5.89e-05	0.000158	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SREBF2—stomach cancer	5.83e-05	0.000157	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MYC—stomach cancer	5.83e-05	0.000157	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HTR1A—stomach cancer	5.83e-05	0.000157	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTGS2—stomach cancer	5.8e-05	0.000156	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PPP2R1A—stomach cancer	5.78e-05	0.000155	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PRKCB—stomach cancer	5.77e-05	0.000155	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—RORA—stomach cancer	5.76e-05	0.000155	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ANXA1—stomach cancer	5.75e-05	0.000155	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK1—stomach cancer	5.71e-05	0.000153	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—EGFR—stomach cancer	5.7e-05	0.000153	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PRKCB—stomach cancer	5.65e-05	0.000152	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ANXA1—stomach cancer	5.63e-05	0.000151	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRB1—stomach cancer	5.57e-05	0.00015	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—RHOA—stomach cancer	5.5e-05	0.000148	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRB1—stomach cancer	5.45e-05	0.000147	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALDOB—stomach cancer	5.4e-05	0.000145	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KRAS—stomach cancer	5.39e-05	0.000145	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SMAD4—stomach cancer	5.37e-05	0.000144	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RPS6—stomach cancer	5.32e-05	0.000143	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCL8—stomach cancer	5.31e-05	0.000143	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PRKCB—stomach cancer	5.24e-05	0.000141	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6ST—stomach cancer	5.22e-05	0.00014	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RPS6—stomach cancer	5.21e-05	0.00014	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PRKCB—stomach cancer	5.13e-05	0.000138	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6ST—stomach cancer	5.11e-05	0.000137	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FYN—stomach cancer	5.1e-05	0.000137	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALOX5—stomach cancer	5.02e-05	0.000135	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PIK3CA—stomach cancer	4.95e-05	0.000133	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—DPYD—stomach cancer	4.94e-05	0.000133	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HBEGF—stomach cancer	4.89e-05	0.000131	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCL8—stomach cancer	4.82e-05	0.00013	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—stomach cancer	4.79e-05	0.000129	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HBEGF—stomach cancer	4.79e-05	0.000129	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FGFR2—stomach cancer	4.79e-05	0.000129	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6R—stomach cancer	4.66e-05	0.000125	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—RHOA—stomach cancer	4.63e-05	0.000124	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HRAS—stomach cancer	4.58e-05	0.000123	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6R—stomach cancer	4.56e-05	0.000122	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—RHOA—stomach cancer	4.53e-05	0.000122	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRB2—stomach cancer	4.52e-05	0.000121	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3CA—stomach cancer	4.43e-05	0.000119	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PPP2R1A—stomach cancer	4.42e-05	0.000119	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRB2—stomach cancer	4.42e-05	0.000119	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—stomach cancer	4.38e-05	0.000118	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IRS2—stomach cancer	4.38e-05	0.000118	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTT1—stomach cancer	4.37e-05	0.000117	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PPP2R1A—stomach cancer	4.33e-05	0.000116	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP2A6—stomach cancer	4.32e-05	0.000116	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CAV1—stomach cancer	4.25e-05	0.000114	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOA1—stomach cancer	4.24e-05	0.000114	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—RHOA—stomach cancer	4.21e-05	0.000113	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKR1C3—stomach cancer	4.2e-05	0.000113	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—RHOA—stomach cancer	4.12e-05	0.000111	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SMAD4—stomach cancer	4.11e-05	0.00011	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ENO1—stomach cancer	4.09e-05	0.00011	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL8—stomach cancer	4.07e-05	0.000109	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PRKCB—stomach cancer	4.04e-05	0.000109	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6ST—stomach cancer	4.03e-05	0.000108	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SMAD4—stomach cancer	4.02e-05	0.000108	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL8—stomach cancer	3.98e-05	0.000107	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FYN—stomach cancer	3.9e-05	0.000105	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APC—stomach cancer	3.87e-05	0.000104	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FYN—stomach cancer	3.82e-05	0.000103	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CA—stomach cancer	3.82e-05	0.000103	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK3—stomach cancer	3.71e-05	9.96e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL8—stomach cancer	3.69e-05	9.92e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGFR2—stomach cancer	3.66e-05	9.84e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CD44—stomach cancer	3.63e-05	9.76e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL8—stomach cancer	3.61e-05	9.71e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6R—stomach cancer	3.59e-05	9.66e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGFR2—stomach cancer	3.58e-05	9.63e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CA—stomach cancer	3.57e-05	9.59e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK1—stomach cancer	3.53e-05	9.48e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—EGFR—stomach cancer	3.53e-05	9.48e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CA—stomach cancer	3.37e-05	9.06e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SERPINE1—stomach cancer	3.37e-05	9.04e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IRS2—stomach cancer	3.35e-05	9.01e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KRAS—stomach cancer	3.33e-05	8.95e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IRS2—stomach cancer	3.28e-05	8.82e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CAV1—stomach cancer	3.25e-05	8.74e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RHOA—stomach cancer	3.25e-05	8.72e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOA1—stomach cancer	3.24e-05	8.72e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NOS3—stomach cancer	3.21e-05	8.63e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CAV1—stomach cancer	3.18e-05	8.55e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOA1—stomach cancer	3.17e-05	8.53e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PRKCB—stomach cancer	3.09e-05	8.32e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPP2R1A—stomach cancer	3.09e-05	8.29e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6ST—stomach cancer	3.08e-05	8.28e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CA—stomach cancer	3.06e-05	8.22e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PRKCB—stomach cancer	3.03e-05	8.14e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTP1—stomach cancer	3.03e-05	8.14e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6ST—stomach cancer	3.02e-05	8.11e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB2—stomach cancer	3.01e-05	8.08e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HMOX1—stomach cancer	2.99e-05	8.02e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APC—stomach cancer	2.96e-05	7.96e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APC—stomach cancer	2.9e-05	7.79e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL8—stomach cancer	2.85e-05	7.66e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK3—stomach cancer	2.84e-05	7.62e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRAS—stomach cancer	2.83e-05	7.61e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMS—stomach cancer	2.81e-05	7.56e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1B—stomach cancer	2.78e-05	7.48e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTM1—stomach cancer	2.78e-05	7.48e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK3—stomach cancer	2.78e-05	7.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6R—stomach cancer	2.75e-05	7.39e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—stomach cancer	2.71e-05	7.28e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK1—stomach cancer	2.7e-05	7.25e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EGFR—stomach cancer	2.7e-05	7.25e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6R—stomach cancer	2.69e-05	7.23e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCND1—stomach cancer	2.66e-05	7.13e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—JUN—stomach cancer	2.65e-05	7.12e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK1—stomach cancer	2.64e-05	7.1e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EGFR—stomach cancer	2.64e-05	7.1e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ERCC2—stomach cancer	2.62e-05	7.03e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CA—stomach cancer	2.58e-05	6.93e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—stomach cancer	2.58e-05	6.93e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SERPINE1—stomach cancer	2.58e-05	6.92e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1A—stomach cancer	2.57e-05	6.9e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KRAS—stomach cancer	2.55e-05	6.85e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CA—stomach cancer	2.52e-05	6.78e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SERPINE1—stomach cancer	2.52e-05	6.77e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK8—stomach cancer	2.51e-05	6.74e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KRAS—stomach cancer	2.49e-05	6.7e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RHOA—stomach cancer	2.48e-05	6.68e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MTHFR—stomach cancer	2.46e-05	6.61e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOS3—stomach cancer	2.46e-05	6.61e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RHOA—stomach cancer	2.43e-05	6.53e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOS3—stomach cancer	2.41e-05	6.47e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CA—stomach cancer	2.34e-05	6.29e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—stomach cancer	2.31e-05	6.22e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB2—stomach cancer	2.3e-05	6.18e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT3—stomach cancer	2.29e-05	6.16e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CA—stomach cancer	2.29e-05	6.16e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CAV1—stomach cancer	2.27e-05	6.1e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOA1—stomach cancer	2.26e-05	6.08e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB2—stomach cancer	2.25e-05	6.05e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK3—stomach cancer	2.19e-05	5.88e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL8—stomach cancer	2.18e-05	5.86e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRAS—stomach cancer	2.17e-05	5.82e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL8—stomach cancer	2.13e-05	5.74e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—stomach cancer	2.13e-05	5.72e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1B—stomach cancer	2.13e-05	5.72e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRAS—stomach cancer	2.12e-05	5.7e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1B—stomach cancer	2.08e-05	5.6e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK1—stomach cancer	2.08e-05	5.6e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGFR—stomach cancer	2.08e-05	5.6e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—stomach cancer	2.07e-05	5.57e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCND1—stomach cancer	2.03e-05	5.46e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—stomach cancer	2.03e-05	5.45e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—JUN—stomach cancer	2.03e-05	5.45e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARG—stomach cancer	1.99e-05	5.36e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCND1—stomach cancer	1.99e-05	5.34e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JUN—stomach cancer	1.98e-05	5.33e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—stomach cancer	1.97e-05	5.3e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KRAS—stomach cancer	1.97e-05	5.29e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1A—stomach cancer	1.97e-05	5.28e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—stomach cancer	1.93e-05	5.19e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1A—stomach cancer	1.92e-05	5.17e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK8—stomach cancer	1.92e-05	5.15e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK8—stomach cancer	1.88e-05	5.04e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CA—stomach cancer	1.81e-05	4.86e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALB—stomach cancer	1.79e-05	4.82e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—stomach cancer	1.77e-05	4.76e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT3—stomach cancer	1.75e-05	4.71e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—stomach cancer	1.75e-05	4.7e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—stomach cancer	1.73e-05	4.66e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT3—stomach cancer	1.72e-05	4.61e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NOS3—stomach cancer	1.72e-05	4.61e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK3—stomach cancer	1.68e-05	4.5e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRAS—stomach cancer	1.67e-05	4.49e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK3—stomach cancer	1.64e-05	4.41e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—stomach cancer	1.63e-05	4.38e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—stomach cancer	1.6e-05	4.3e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—stomach cancer	1.59e-05	4.29e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK1—stomach cancer	1.59e-05	4.28e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGFR—stomach cancer	1.59e-05	4.28e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—stomach cancer	1.57e-05	4.22e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK1—stomach cancer	1.56e-05	4.19e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGFR—stomach cancer	1.56e-05	4.19e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KRAS—stomach cancer	1.51e-05	4.05e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KRAS—stomach cancer	1.47e-05	3.96e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CA—stomach cancer	1.38e-05	3.72e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CA—stomach cancer	1.35e-05	3.64e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—stomach cancer	1.34e-05	3.6e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—stomach cancer	1.31e-05	3.52e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRAS—stomach cancer	1.28e-05	3.44e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRAS—stomach cancer	1.25e-05	3.37e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—stomach cancer	1.23e-05	3.29e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—stomach cancer	1.2e-05	3.22e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CA—stomach cancer	9.65e-06	2.59e-05	CbGpPWpGaD
